The blue-chip FTSE 100 added 0.2% to hold near 10-week highs, while the midcap FTSE 250 index inched up 0.1%
UK’s FTSE 100 edged up on Monday as gains in drugmaker AstraZeneca and consumer stocks relieved pressure from mining and oil heavyweights after data showed China’s economy unexpectedly slowed last month.
The blue-chip FTSE 100 added 0.2% to hold near 10-week highs, while the midcap FTSE 250 index inched up 0.1%.
Investors are awaiting the UK employment report as well as consumer prices data later this week to gauge the state of the labour market and inflation.
The data could offer clues on whether the Bank of England opts for a second consecutive 50-basis-point-rate hike at its September meeting.
The mood was dull in Asian and European stock markets, with investors turning to defensive sectors such as healthcare and consumer staples amid worries about the health of the world’s second-largest economy.
AstraZeneca gained 2.6% after the drugmaker said its cancer drug, Enhertu, developed with Japan’s Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients.
Oil major Shell and miners Rio Tinto and Anglo American slipped, in tandem with weaker commodity prices, after the release of the China data.
The FTSE 100 has outperformed its global peers this year due to its large exposure to commodity stocks that have surged on the back of a jump in oil and metal prices. A weakening pound has also boosted dollar earners in the index.
Whether this trend will continue ultimately hinges on the outlook for global energy stocks relative to the broad market, BCA Research analysts wrote in a note.
The FTSE 100 is up nearly 2% so far this year, while the MSCI world equities index has shed almost 13%.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.